Taboo populations, foods, and restrictions of Lenalidomide in Laos' Lusius version
The contraindications of Lenalidomide involve specific populations, dietary restrictions, and medication conditions, and must be strictly followed to avoid serious risks. The following provides a detailed explanation from three aspects: the classification of taboo populations, taboo foods, and special restriction conditions, based on drug instructions and clinical guidelines.
1. Taboo population
(1) Pregnant women
Lenalidomide has clear teratogenicity and is absolutely contraindicated during pregnancy. Pregnancy status should be confirmed before medication, and dual contraception measures should be taken during treatment and 4 weeks after discontinuation of medication.
(2) Lactating women
Medications may be secreted through breast milk, and medication or breastfeeding should be discontinued during lactation. There is no safety data available to support breastfeeding use.
(3) Severe liver dysfunction
Child Pugh Class C patients are contraindicated. Moderate to severe liver damage requires dose adjustment and close monitoring of transaminase and bilirubin levels.
(4) Uncontrolled hypertensive patients
Due to the increased risk of thrombosis, those with blood pressure>140/90mmHg who have not been controlled should temporarily suspend medication and evaluate after blood pressure stabilizes.
2. Forbidden foods
(1) Grapefruit and its products
Containing strong CYP3A4 inhibitors can significantly increase blood drug concentration and increase the risk of adverse reactions. During treatment, ingestion should be completely avoided.
(2) High-fat diet
Avoid consuming high-fat foods while taking medication, as it may delay drug absorption. It is recommended to take it on an empty stomach or 2 hours after a meal.
(3) Alcoholic beverages
May increase the metabolic burden on the liver and increase the risk of liver toxicity. During treatment, one should quit drinking or strictly limit their intake.
3. Restrictive conditions
(1) Renal function adjustment
Creatinine clearance rate<60mL/min needs to be reduced, and<30mL/min is prohibited. Dialysis patients need to receive medication after dialysis.
(2) Combination medication restrictions
The combination of potent CYP3A4 inducers (such as rifampicin) is prohibited as it may lead to treatment failure. At least a 2-week interval is required.
(3) Treatment cycle control
Patients with multiple myeloma should not use it continuously for more than 24 cycles, and the efficacy and safety should be evaluated regularly.
(4) Vaccination contraindications
Vaccination with live vaccines may cause infection, and vaccination with live vaccines is prohibited during treatment and for 3 months after discontinuation of medication.
Disclaimer：《Taboo populations, foods, and restrictions of Lenalidomide in Laos' Lusius version》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！